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AZTREONAM LYSINE INHALATION SOLUTION (AZLI, CAYSTON®, GILEAD) STABILISES LUNG FUNCTION DECLINE IN 
PATIENTS WITH CYSTIC FIBROSIS AND MODERATE TO SEVERE LUNG DISEASE 
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ABSTRACT BODY: 
Introduction: P. aeruginosa (PA) is the most common pathogen and is associated with worse lung function, nutrition 
and increased mortality. Aztreonam lysine inhalation solution (AZLI, Cayston®, Gilead) is licenced for use in patients 
with CF aged six years and older, with chronic PA (CPA). The aim of this audit was to assess the usage and clinical 
outcome of AZLI in a large adult CF unit. 
Methods: Data was extracted between 2011 and 2017. A total of 168 patients received at least one dose of AZLI. 
Indications included CPA, PA eradication and combination therapy in acute exacerbations. Patients who received at 
least 50% of doses (91/168 patients) were included with 15 subjects being excluded due to pregnancy, lung 
transplant and recent treatment. Data was extracted for age, weight, BMI, lung function, CRP, plasma viscosity (PV), 
white cell count (WCC), and days of IVs . 
Results: A total of 76 patients met inclusion criteria; PA (n=62) and Burkholderia Cepacia Complex (BCC) +/- PA 
(n=14). Of these 76 patients, 3 died within 1 year of prescription of AZLI, 4 died within 2 years, and 6 died within 3 
years. Prior to the initiation of AZLI, the majority of patients had failed to respond to alternative inhaled 
antipseudomonal treatment; promixin monotherapy (PA n=17; BCC/PA n=2), tobramycin monotherapy (PA n=28; 
BCC/PA n=8), or a combination of the 2 treatments (PA n= 14; BCC/PA n=2). AZLI was prescribed on an alternate 
month basis with another agent in 49 PA (20 promixin, 29 tobramycin) and 8 BCC patients (3 promixin, 5 
tobramycin). There were no differences in clinical characteristics at baseline between PA and BCC patients except for 
weight where BCC patients were heavier. AZLI therapy was initiated in patients with low FEV1. In both groups there 
was a significant decline in FEV1 prior to initiating therapy (p<0.001) which subsequently stabilised (NS). There was a 
significant increase in CRP and PV in patients with PA over the study period (Table).  
Conclusion: AZLI therapy stabilises lung function decline in patients with PA even with moderate and severe disease. 
Data suggests that AZLI was being prescribed late in the disease course and should be considered sooner. Further 
work to assess adherence to therapy is needed. 
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Table: Within and between group effects (PA v BCC) from 1 year pre-AZLI to 1 year post 
Patient 
characteristic 
  
1 year pre- 
AZLI 
Baseline 
1 year post 
AZLI 
Within Group 
effect 
Between Group 
effect 
Weight (Kg) 
PA 
BCC 
62.7(±11.9) 
68.8(±12.6) 
62.9(±12.0) 
68.1(±13.1) 
62.8(±12.2) 
68.5(±13.7) 
p = 0.88 
p = 0.82 
p = 0.62 
BMI (Kg/m2) 
PA 
BCC 
22.0(±3.0) 
23.6(±3.0) 
22.1(±3.1) 
23.4(±3.1) 
22.1(±3.1) 
23.5(±3.1) 
p = 0.42 
p = 0.83 
p = 0.58 
FEV1 (%) 
PA 
BCC 
46.2(±14.7) 
50.4(±15.1) 
42.6(±14.2) 
46.8(±15.5) 
40.7(±14.8) 
43.9(±15.1) 
p < 0.001 
p = 0.008 
p = 0.82 
FVC (%) 
PA 
BCC 
66.1(±17.4) 
72.5(±16.3) 
62.8(±16.3) 
68.5(±17.8) 
60.6(±18.6) 
65.4(±18.3) 
p < 0.001 
p = 0.02 
p = 0.62 
 
CRP 
PA 
BCC 
16.6(±10.6) 
19.8(±17.2) 
22.4(±17.9) 
15.4(±9.4) 
24.5(±20.0) 
25.9(±26.4) 
p = 0.005 
p = 0.23 
p = 0.17 
PV 
PA 
BCC 
1.8(±0.13) 
1.83(±0.11) 
1.83(±0.17) 
1.84(±0.08) 
1.85(±0.19) 
1.85(±0.11) 
p = 0.004 
p = 0.89 
p = 0.37 
WCC 
PA 
BCC 
6.7(±2.2) 
7.7(±2.8) 
6.8(±2.1) 
7.6(±2.3) 
7.1(±2.5) 
7.9(±3.0) 
p = 0.08 
p = 0.79 
p = 0.73 
 
Days of IVs  
PA 
BCC 
13.9(±7.0) 
6.8(±11.5) 
15.5(±7.6) 
20.3(±21.4) 
17.1(±13.2) 
14.1(±7.7) 
p = 0.09 
p = 0.36 
p = 0.07 
 
